Background. The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of
extended-spectrum β-lactamase (ESBL) bacteremia is controversial. We compared 14-day …

Abstract (See the Editorial Commentary by Perez and Bonomo, on pages 175–7.)
Background. Extended-spectrum ß-lactamase–producing Escherichia coli (ESBL-EC) is an …

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a common
cause of bacteraemia in endemic countries and may be associated with high mortality; …

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)–
producing pathogens is recognized globally as one of the most pressing concerns facing the …

Objectives To study the comparative mortality associated with carbapenems and alternative
antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive …

Therapy of infections caused by extended‐spectrum β‐lactamase (ESBL)‐producing
bacteria with an antimicrobial to which they are resistant results in treatment failure, higher …

Background The objective of this study is to analyze the factors that are associated with the
adequacy of empirical antibiotic therapy and its impact in mortality in a large cohort of …

Traditionally, physicians have not used cefepime (a fourth-generation cephalosporin with
greater stability against β-lactamases) or β-lactam/β-lactamase inhibitors (BLBLIs) for …

We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39
bloodstream infections due to extended-spectrum-β-lactamase-producing Escherichia coli …

Background Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae are
often susceptible in vitro to β-lactam/β-lactamase inhibitor (BLBLI) combination antibiotics …